As soon as January, two vaccines may be ready to deploy for the heavy hitting Ebola areas of Guinea, Liberia and Sierra Leone. The vaccines must pass human safety trials where twenty human subjects receive injections in the United States. Researchers hope to know about safety results by late November or early December. WHO especially expresses interest in one of the vaccines from GlaxoSmithKline. Fauci:
I don’t know if that’s going to be the best one, but that’s the one farthest along in terms of development.
A Canadian company ships 800 vials for testing in the hopes that WHO approves. Kieny:
These data are absolutely crucial to allow decision-making on what dose level should go in the efficacy testing in Africa. We expect, we hope, to have a go-ahead by the end of the month.
Both of these vaccines are the top choices for availability and production. They’re not ready for prime time if it wasn’t an emergency situation, but they are the ones the World Health Organization is supporting.